Hims & Hers Health, Inc. (HIMS)
| Market Cap | 10.76B |
| Revenue (ttm) | 2.01B |
| Net Income (ttm) | 193.60M |
| Shares Out | 226.02M |
| EPS (ttm) | 0.79 |
| PE Ratio | 60.38 |
| Forward PE | 64.87 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,566,078 |
| Open | 48.83 |
| Previous Close | 48.11 |
| Day's Range | 46.86 - 49.16 |
| 52-Week Range | 13.47 - 72.98 |
| Beta | 2.14 |
| Analysts | Hold |
| Price Target | 37.20 (-21.88%) |
| Earnings Date | Nov 3, 2025 |
About HIMS
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supp... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for HIMS stock is "Hold." The 12-month stock price target is $37.2, which is a decrease of -21.88% from the latest price.
News
Hims & Hers Health: Still Undervalued
Hims & Hers is fundamentally undervalued, trading at a forecast P/S ratio of 3.5 despite strong 88% YoY growth and European expansion. Low valuation and scaling by ZAVA lead to a buy rating. Short int...
Hims & Hers: The Dominant Health Platform Of The Future
Hims & Hers is evolving into a robust health platform, showing strong subscriber growth, rising ARPU, and expanding into weight loss, hormone health, labs, and international markets. Q2 results confir...
Rocket, Oscar, Hims & Hers: Short Sellers Are Playing With Fire
Wall Street's most crowded shorts are starting to look like powder kegs. Rocket Companies Inc RKT, Oscar Health Inc OSCR, and Hims & Hers Health Inc HIMS are sitting at the top of the market's short-i...
Hims & Hers Health, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - HIMS
LOS ANGELES , Aug. 25, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims & Hers" or "the Company") (NYSE: HIMS)...
Hims & Hers (HIMS) Stock Lawsuits: Investors Urged to Act - Hagens Berman
SAN FRANCISCO, Aug. 24, 2025 (GLOBE NEWSWIRE) -- Investors who lost money in Hims & Hers (NYSE: HIMS) are being urged to actively participate in a securities class action lawsuit. The lawsuit alleges ...
Hims & Hers: Personalized Care To Sustain Revenue Growth Despite GLP-1 Hiccup
I remain bullish on Hims & Hers Health due to its resilient subscriber growth and strong positioning in the expanding personalized care and telehealth markets. Despite the loss of the GLP-1 contract w...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options If you purchased or acquired se...
Here's How I Am Buying Hims & Hers At $37 Or Earning 4.2% Monthly Instead
Hims & Hers is undervalued, rapidly scaling a vertically integrated, consumer-focused healthcare platform with 73% YoY revenue growth and strong EBITDA margins. Market fears over GLP-1 regulatory chan...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 25, 2025 in Hims & Hers Health, Inc. Lawsuit – HIMS
NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS).
Why is GDRX stock up 30% today? GoodRx strikes deal to sell Ozempic and Wegovy after Novo Nordisk's breakup with Hims
Share prices of GoodRx (NASDAQ: GDRX), the American healthcare company and telemedicine service, are currently soaring after the company announced that it will partner with Novo Nordisk to offer the l...
HIMS' Transformation Into A Precision Health Platform
Hims & Hers posted 73% year-over-year revenue growth in Q2 2025, driven by 31% subscriber expansion and ~30% ARPU increase. Monthly online revenue per subscriber reached $74, equating to an annualized...
US FTC investigating Hims & Hers over advertisements and cancellation practices, Bloomberg News reports
The U.S. Federal Trade Commission is probing complaints about Telehealth platform Hims & Hers regarding its advertising and cancellation practices, according to a Bloomberg News report citing people f...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options If you purchased or acquired se...
Hims & Hers CEO sells $33 million in stock after a massive rally
The company says the sales came from indirect holdings and were for “tax and philanthropic purposes.”
Why is Novo Nordisk excluding Hims & Hers in its lawsuits over Wegovy copies?
In Novo Nordisk's legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug Wegovy, one name remains conspicuously absent: Hims & Hers. The high-profil...
As Novo Nordisk ramps up lawsuits over Wegovy copies, investors ask where is Hims?
In Novo Nordisk's legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug Wegovy, one name remains conspicuously absent: Hims & Hers.
Hims & Hers: A High-Risk Bet
Upgrading Hims & Hers Health, Inc. to a speculative Buy after a 20% post-earnings selloff, given management's reaffirmed guidance and near-term demand for personalized compounded GLP-1s. I believe the...
Hims & Hers: From Telehealth To Wellness Hub, The Bright Future
I remain bullish on Hims & Hers Health, viewing the recent price dip as a buying opportunity given its strong long-term prospects. Technological innovation and personalized care, including at-home lab...
Hims & Hers: Still Growing After Breakup With Novo Nordisk
Hims & Hers is positioned as a leading telehealth platform targeting millennial and Gen Z consumers with affordable, accessible healthcare solutions. The company's strong revenue growth, expanding pro...
Hims & Hers: GLP-1 Strategy Is On Dubious Grounds
Hims & Hers Health showed a sharper-than-expected revenue hiccup in Q2, sending the stock down. The results reflect GLP-1 concerns. Hims & Hers' GLP-1 strategy is now on dubious grounds after Novo Nor...
Wait Out The GLP-1 Storm - Buy The Hims And Hers Post-Earnings Dip
Hims and Hers faced a short-term revenue dip due to regulatory changes and GLP-1 customer offboarding, but core growth remains strong. Subscriber numbers surged 31% quarter-over-quarter, and product d...
Weighing HIMS GLP-1 Trends, NVO Partnership & Other Businesses
Michael Cherny sees opportunity for Hims & Hers (HIMS), as long as it can overcome headwinds facing its non-weight loss businesses. He argues the stock hasn't traded on fundamentals and weighs heavily...
Hims & Hers drops on revenue miss
CNBC's Brandon Gomez joins 'Squawk on the Street' to discuss the latest earnings from Hims & Hers.
Hims & Hers Health Posts Weak Q2; Heading Into More Near-Term Challenges, Analysts Say
Shares of Hims & Hers Health Inc HIMS are under pressure Tuesday, after the company reported downbeat second-quarter revenues.
Hims & Hers falls as declining subscriber base weighs on revenue
Shares of telehealth firm Hims & Hers fell as much as 5% on Tuesday after the company reported weaker-than-expected second-quarter revenue, hurt by a loss of subscribers in its weight-loss treatment a...